Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by SOTIO Biotech

SOTIO to Present Data Highlighting Progress Across ADC and Immunocytokine Programs at Upcoming Scientific Conferences
From SOTIO Biotech
Via Business Wire
SOTIO Strengthens Leadership Team with Appointments of Amy Jensen-Smith as Chief Scientific Officer and Ulrich Moebius as Chief Development Officer
From SOTIO Biotech
Via Business Wire
SOTIO Reports Promising Preclinical Data on Antibody-Drug Conjugates SOT109 and SOT106, Underscoring Best-in-Class Potential for Solid Tumor Treatments
From SOTIO Biotech
Via Business Wire
SOTIO to Present Preclinical Data on Lead Antibody-Drug Conjugates, SOT106 and SOT109, at 2025 AACR Annual Meeting
From SOTIO Biotech
Via Business Wire
SOTIO Expands ADC Pipeline and Synaffix Collaboration to Develop Two Novel Bispecific Candidates, SOT112 and SOT113
From SOTIO Biotech
Via Business Wire
SOTIO Unveils Promising Preclinical Data on SOT109, a Next-Gen ADC Targeting Cadherin-17 (CDH17) for Colorectal Cancer
From SOTIO Biotech
Via Business Wire
SOTIO Advances Colorectal Cancer ADC Program, SOT109, and Licenses Fully Human Antibodies from Biocytogen for Novel Tumor Target
From SOTIO Biotech
Via Business Wire
SOTIO Showcases New Data on SOT201 Immunocytokine, VICTORIA-01 Clinical Study, and BOXR CAR-T Advancements at 2024 SITC Annual Meeting
From SOTIO Biotech
Via Business Wire
SOTIO Announces Upcoming Poster Presentations at the 2024 SITC Annual Meeting
From SOTIO Biotech
Via Business Wire
SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline
From SOTIO Biotech
Via Business Wire
SOTIO Announces First Patient Dosed in Phase 1 Clinical Study of SOT201 for Patients with Solid Tumors
From SOTIO Biotech
Via Business Wire
SOTIO Presents Overview of DUET-01 Phase 1/2 Study at ASCO Annual Meeting
From SOTIO Biotech
Via Business Wire
SOTIO to Present Poster on DUET-01 Clinical Trial at 2024 ASCO Annual Meeting
From SOTIO Biotech
Via Business Wire
SOTIO Presents New Preclinical Data on Enhanced CAR T-Cell Therapies at AACR Annual Meeting
From SOTIO Biotech
Via Business Wire
SOTIO Presents Data on SOT201 Immunocytokine and Other Programs at SITC Annual Meeting
From SOTIO Biotech
Via Business Wire
SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix’s ADC Technology
From SOTIO Biotech
Via Business Wire
SOTIO Provides Update on Interim Data from Clinical Trials of Nanrilkefusp Alfa
From SOTIO Biotech
Via Business Wire
SOTIO Announces First Patients Dosed in Two Combination Arms of CLAUDIO-01 Study Evaluating SOT102 in First-Line Gastric and Pancreatic Cancer
From SOTIO Biotech
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.